ClinicalTrials.gg
Not yet recruitingNCT07937501Updated Nov 16, 2026

A Study of IPG11406 Tablets in Participants With Lupus Nephritis

A Phase 2 interventional study of IPG11406 tablet and placebo in Lupus Nephritis, sponsored by Nanjing Immunophage Biotech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Planned enrollment
19th of 88
192 · median 51
Started
2026
with 10 others
Phase 2
19 of 96
8 open now
Primary completion
2028-11
later than 38 of 45 live
Registered
96th of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 19th largest by planned enrollment of the 88 interventional ones that give a count, is one of 11 that started in 2026, is one of 19 in phase 2, reaches primary completion later than 38 of the 45 other live ones, and was the 96th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

Lupus Nephritis (LN) is one of the most serious and common complications of Systemic Lupus Erythematosus (SLE). It is a chronic inflammatory disease triggered by abnormal autoimmunity and the deposition of immune complexes in the kidneys. Approximately 40% to 60% of SLE patients develop lupus nephritis at the onset of the disease, and the cumulative rate of kidney involvement during the course of the disease can even reach 90%.

The goal of this Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis trial is to evaluate the efficacy ,safety and tolerability of different doses of IPG11406 tablets combined with standard treatment compared to placebo combined with standard treatment in participants with active lupus nephritis.

A total of 4 groups were designed the 10mg IPG11406 tablet group, the 20mg IPG11406 tablet group, the 40mg IPG11406 tablet group,and the placebo group. The ratio among the groups was 1:1:1:1. Participants were randomly assigned to the above 4 dosage groups, with 48 participants planned for each group, totaling approximately 192 participants enrolled.

After randomization, participants will receive a 24-week double-blind treatment, twice daily (BID).They will take the assigned study drug (IPG11406 tablets at 40mg, 20mg, 10mg or placebo) orally.Throughout the 24-week core treatment period, all participants in all groups should continue to receive the standard treatment as prescribed by the protocol.

The primary efficacy endpoint of the renal response will be determined by changes in proteinuria and renal function. For the renal function assessment in the study visits, the glomerular filtration rate will be estimated using the CKD-EPI formula; proteinuria will be evaluated using the urine protein-to-creatinine ratio (based on the 24-hour urine collected).

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 - 70 years old (inclusive of 18 and 70), gender not restricted.
  2. Participants must meet the SLICC (Systemic Lupus International Collaborating Clinics, SLICC) criteria and have been diagnosed with systemic lupus erythematosus before screening.
  3. The 24-hour urine total protein of the participants is ≥ 1g or the urine protein-to-creatinine ratio (UPCR) is ≥ 1g/g (based on the collected 24-hour urine sample).
  4. The estimated (eGFR) calculated using the CKD-EPI formula is > 45 ml/min/1.73 m\^2.
  5. According to the 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria, there is active, -proven type III or IV lupus nephritis (with or without type V); if there is no biopsy result from the 6 months before the screening visit, a biopsy must be conducted during the screening period to determine if the participant meets this inclusion criteria.
  6. According to the researcher's opinion, the participant has active lupus nephritis and requires induction therapy with high-dose combined with mycophenolate mofetil.
  7. The participant is willing to take oral mycophenolate mofetil (MMF) during the study period. If the participant has previously taken MMF, they can continue with the previous MMF treatment. If the participant has not taken MMF before, it can be initiated based on the baseline.
  8. For participants who are taking drugs that may affect renal function (such as antihypertensive drugs, lipid-lowering drugs), the dose must be stable for at least 4 weeks before randomization and during the study period.
  9. Female participants with (defined as not undergoing surgical sterilization or having been for less than 1 year) must undergo a blood pregnancy test during the screening visit and the result must be negative; female or male participants with reproductive potential must have no pregnancy plans for at least 30 days before the first administration and within 6 months after the study, voluntarily take effective measures (see attachment), and have no sperm donation or egg donation plans.
  10. Participants voluntarily participate in the study, understand and sign the form, and comply with the requirements in the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have previously been treated with the following medications and are expected to still be within the drug when the study drug is administered:

    a. Taltazyme: 2 months; b. Belimumab: 2 months; other biologic B-cell targeted therapies: 2 months; c. Within 2 months before screening or during screening, oral administration of any JAK inhibitor, Bruton's tyrosine kinase (BTK) inhibitor, or tyrosine kinase 2 (TYK2) inhibitor, including baricitinib, tofacitinib, upadacitinib, fingolimod, ibrutinib, or fenbetidine; d. Participants who have received CAR-T therapy cannot be enrolled. e. Within less than 9 months before screening or during screening, any anti-CD20 therapy (such as rituximab, ofatumumab, or oriximab), CD19 targeted therapy, if received between 9 and 12 months before screening, peripheral blood CD19⁺ B cell count must be ≥ 25 cells/μL.

  2. Participants who received cyclophosphamide (CYC) induction therapy within 1 month before screening.
  3. Participants who used any immunomodulatory drugs or herbal preparations with potential impact on liver and kidney function within 4 weeks before screening, including but not limited to Tripterygium glycosides tablets, drugs containing aristolochic acid (such as Dragon's Liver-Clearing Pills, Coronary Heart-Soothing Pills, etc.), and known hepatotoxicity-laden ingredients such as Notoginseng and Tongshiguaiwu.
  4. Participants with interstitial fibrosis/tubular atrophy (IF/TA) or glomerular sclerosis exceeding 50% in renal tissue .
  5. Participants with rapidly progressive glomerulonephritis, as defined by any of the following:

    • Renal biopsy assessment shows that ≥ 50% of glomeruli have crescent formation
    • Serum creatinine has continuously doubled within 2 months before screening
    • The investigator believes that the participant has rapidly progressive glomerulonephritis
  6. Primary glomerular diseases or secondary nephropathy caused by systemic lupus erythematosus, including diabetic nephropathy, hypertensive renal damage, anti-glomerular basement membrane disease, viral hepatitis-related nephropathy, -related nephropathy, purpura nephritis, paraproteinemia-related nephropathy, drug or toxin-related nephropathy, etc., which the investigator believes may interfere with LN assessment and will interfere with the assessment results of disease activity.
  7. Participants at the time of screening visit still have ≥ 2 grade adverse events related to previous drug treatment (see the main text of the protocol - adverse event grading), or adverse events that affect the participant's inclusion/exclusion criteria judgment and/or participant's efficacy/safety assessment.
  8. Participants who previously had or currently have severe neuropsychiatric SLE, including but not limited to the following: seizure, new or worsening impairment of consciousness, psychosis, delirium or confusion state, sterile meningitis, ascending or transverse myelitis, chorea, cerebellar ataxia, multiple mononeuritis, demyelinating syndrome or situations that prevent the participant from fully understanding ICF.
  9. Any overlapping diseases whose condition or treatment may affect the assessment or outcome of this study (such as scleroderma with significant pulmonary hypertension; any disease that requires additional treatment), must be excluded. If the condition or treatment of overlapping diseases is expected not to affect the assessment or outcome of the study (such as Sjogren's syndrome), it is not excluded. Participants.
  10. Participants who have had malignant tumors within the past 5 years.
  11. Participants with active antiphospholipid antibody syndrome (APS) or requiring therapeutic anticoagulation.
  12. Participants currently requiring renal dialysis (hemodialysis or peritoneal dialysis), or expected to require renal dialysis during the study.
  13. Participants with a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplantation.
  14. Participants who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within the previous 4 weeks or have unhealed wounds, ulcers or fractures.
  15. Participants who have received live/dead attenuated vaccinations or plan to receive live/dead attenuated vaccinations during the trial.
  16. Participants with any of the following cardiac impairments: a. functional classification grade III to IV; b. Uncontrolled angina pectoris, congestive heart failure or myocardial infarction within 6 months before the first dose administration; c. interval prolonged by Fridericia formula (male > 450 milliseconds; female > 470 milliseconds); d. Second-degree type II atrioventricular (AV) block, third-degree AV block or PR interval > 250 milliseconds, etc.; e. Various factors that may increase the risk of QTcF prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, and first-degree relatives in the family history had sudden death before the age of 40; f. (LVEF) \< 50%.
  17. Participants who are receiving treatment for chronic or recurrent infections, such as tuberculosis, pneumocystis pneumonia, herpes simplex virus and varicella-zoster virus.
  18. Participants with positive in the five-antibody test for hepatitis B (those with negative HBsAg but positive HBcAb need to do HBV-DNA quantitative test; those with HBV-DNA test result ≥ upper limit of reference value of each center or those requiring antiviral treatment do not meet the conditions for participating in the study); positive antibody (add HCV-RNA test if negative; those who are negative can be enrolled); positive Treponema pallidum antibody (if Treponema pallidum antibody is positive, further Treponema pallidum serological test is conducted; participants judged by the investigator as having had a past infection with syphilis but having been cured meet the inclusion criteria); positive HIV antibody test.
  19. Participants with significantly abnormal liver, kidney function and blood routine test results, including: (ALT) and/or aspartate aminotransferase (AST) exceeding 2 times the value, serum total exceeding 1.5 times the upper limit of normal value; \< 90 g/L; white blood cell count \< 3.0×10\^9/L, count (PLT) \< 75×10\^9/L; \< 1.0×10\^9/L; and other abnormal laboratory test results, as determined by the investigator, may affect the participant's ability to complete the entire clinical research process or interfere with the safety/efficacy results of the study.
  20. Participants have any condition that may prevent them from safely completing all clinical research procedures, such as being allergic to the test drug (including ), having a severe allergic disease or being of an allergic constitution, having a known difficulty in swallowing, experiencing anemias or needle phobia, being intolerant to oral or intravenous or having , or being intolerant to mycophenolate mofetil.
  21. Participants have any of the following major infection events:

    • Hospitalized within the previous 8 weeks or during the screening period
    • Received intravenous antibiotics or anti-infective drugs during the screening period
    • Received oral antibiotics or anti-infective drugs within the previous 2 weeks or during the screening period
  22. Note: If only using antibiotics or anti-infective drugs without major infection events does not constitute an exclusion criterion.
  23. Participants have a history of drug abuse or drug misuse.
  24. Pregnant or lactating female participants.
  25. Participants who have participated in other clinical studies within 180 days before the screening, or who plan to participate in other clinical studies before the completion of all planned visits of this clinical study;
  26. Other situations judged by the investigator as not suitable for inclusion.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    10mg IPG11406 tablet group

    Drug: IPG11406 tablet · Drug: placebo

  • Experimental
    20mg IPG11406 tablet group

    Drug: IPG11406 tablet · Drug: placebo

  • Experimental
    40mg IPG11406 tablet group

    Drug: IPG11406 tablet

  • Placebo comparator
    the placebo group

    Drug: placebo

Interventions

  • DrugIPG11406 tablet

    Twice daily, oral administration for 24 weeks.

  • Drugplacebo

    Twice daily, oral administration for 24 weeks.

06

What researchers measure

Primary outcomes

  1. The proportion of participants who achieved complete renal remission (Completerenalresponse, CRR) at the 24th week.

    The definition of CRR is as follows: 1. The urine protein/urine creatinine ratio (UPCR, based on the 24-hour urine sample collected) is less than 0.5g/g; 2. The reduction in glomerular filtration rate (eGFR) is ≤ 15% of the baseline value or eGFR is ≥ 90 mL/min/1.73m\^2; 3. There are no concurrent conditions such as rescue treatment, treatment failure, death, or withdrawal from the study.

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 site
  • Nanjing DrumTower Hospital
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Nov 20, 2028
CompletionEst.
Nov 20, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937501
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Nov 20, 2028 (estimated)
Completion
Nov 20, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Qiaofeng Qu, Master
Contact
qfqu@immunophage.com.cn
+8621 34782827

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion